MedTrace Logo

DESolve® X-Pand Global Post Market Registry

NCT02453035 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 154

Last updated 2021-04-26

No results posted yet for this study

Summary

The X-Pand Registry is intended to facilitate analysis of acute \& long-term safety as well as treatment outcomes with DESolve in patients with CAD.

Conditions

  • Coronary Artery Stenosis

Interventions

DEVICE

PTCA - Desolve Scaffold

Percutaneous Coronary Artery Intervention with a DESolve bioresorbable coronary scaffold

Sponsors & Collaborators

  • European Cardiovascular Research Center

    collaborator NETWORK

  • Elixir Medical Corporation

    lead INDUSTRY

Principal Investigators

  • Jean Fajadet, Dr. · University Hospital of Toulouse

  • Holger Nef, Prof Dr. · Universitätsklinikum Giessen und Marburg

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-13
Primary Completion
2017-03-31
Completion
2017-04-30

Countries

  • Germany
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02453035 on ClinicalTrials.gov